QURE · uniQure N.V.

The thesis

uniQure's Huntington's disease gene therapy, AMT-130, is under FDA review on three-year data, and the four-year update of 29 September 2026 weakened the evidence around it. The FDA's decision on whether to accept the application, due around 1 November 2026, and the 4 November 2026 third-quarter report settle whether the shares recover.

The company submitted the biologics license application (BLA) on 2 September 2026 and asked for priority review. The filing rests on the 36-month analysis, not the 48-month one. Adjusted daily closes show $24.97 on 28 October 2026, up from $22.52 on 15 October 2026 but 64.6% below the $70.59 52-week high. The three-month change is -42.8%, and the 14-day relative strength index (RSI) has moved from 13.5 to 62.0 over those two weeks.

The narrative is maturing and under strain: coverage is heavy, and analysts cut targets after the 29 September 2026 data. Barclays downgraded the shares to Equal-Weight with a $28 target on 5 October 2026. Goldman Sachs holds Neutral with a $31 target (30 September 2026). RBC Capital holds Outperform with a $48 target (2 October 2026). Company news through 28 October 2026 contains only the announcement of the report date, and no SEC filing has appeared since the 29 September 2026 update.

Bullish and bearish views on uniQure N.V.

The bull case on uniQure N.V. (QURE), in brief: The company said on 17 June 2026 that the FDA would accept the three-year analysis as the primary basis for an accelerated-approval BLA. The bear case: The headline efficacy measure weakened.

Bull case

• The company said on 17 June 2026 that the FDA would accept the three-year analysis as the primary basis for an accelerated-approval BLA.
• Functional and biomarker signals held at four years. High-dose patients showed 61% slowing on Total Functional Capacity versus the Enroll-HD B external control (p=0.008), per the 29 September 2026 release. Cerebrospinal fluid neurofilament light chain, a marker of nerve damage, was 4% above baseline at 48 months.
• Safety remained manageable. The company reported one treatment-related central nervous system inflammation case since September 2025, resolved with corticosteroids (press release, 29 September 2026).
• Cash covers the review period. uniQure held $810.3M in cash, equivalents and current investment securities at 30 June 2026, and says operating expenses are funded into 2030 (Q2 2026 results, 29 July 2026). The company also priced an upsized $225M public offering at $45.50 per share on 24 June 2026.
• Some analysts still see value. RBC Capital's $48 target (2 October 2026) sits well above the $24.97 close of 28 October 2026. Barclays' $28 target (5 October 2026) and Goldman Sachs' $31 target (30 September 2026) are also above it.

Bear case

• The headline efficacy measure weakened. The composite Unified Huntington's Disease Rating Scale (cUHDRS) slowing in the high-dose group fell from 75% at three years to 44% at four years against the updated control, with a nominal p-value of 0.144 (company release, 29 September 2026). Investing.com reported the shares fell 37% on 29 September 2026.
• The control group is contested. uniQure attributes the weaker result to survivor bias in the updated Enroll-HD B control, where 53% of data was missing at month 48. A comparison that shifts with the choice of control gives the FDA room to discount it.
• The sample is small. The 48-month high-dose analysis covers 12 of the 17 patients dosed at baseline, and the low-dose group has 12 (company release, 29 September 2026). Groups this size cannot establish durability.
• Regulatory repricing risk. Ortex reported on 30 September 2026 that the shares fell 46% in five sessions to $24.51. It read the move as investors pricing a higher chance that the FDA returns to requiring a randomized, sham-surgery-controlled trial.
• Analyst sentiment turned down. Goldman Sachs cut its target from $46 to $31 (30 September 2026), and Barclays moved to Equal-Weight with a $28 target (5 October 2026). The June 2026 targets, such as HC Wainwright's $80 (29 June 2026) and Mizuho's $68 (25 June 2026), predate the four-year data.

Price setup

The shares closed at $24.97 on 28 October 2026 (adjusted daily closes). That is 64.6% below the $70.59 52-week high and close to the $24.51 level Ortex reported on 30 September 2026, after the data selloff. The close of 15 October 2026 was $22.52.

The two-week rebound lifted the 14-day RSI from 13.5 to 62.0. The shares remain well under the $45.50 June offering price. A decisive move above the post-data range needs the FDA outcome; the price has not yet reacted to the filing decision because it has not been announced.

Crowding evidence is limited to an imminent binary event. The FDA's 60-day filing review ends around 1 November 2026, and the earnings report follows on 4 November 2026. No Form 4 insider transactions appear in company news over the period.

Catalysts, next 30 days

No upcoming dated catalysts on file — the dated entries below have passed.

Elapsed catalysts

• ~1 November 2026 (est.), FDA filing decision. The 60-day review of the 2 September 2026 BLA ends. Acceptance with priority review would pull the approval decision into 2027, a refusal to file or standard review would reset the timeline. The company said management expects an advisory committee meeting to be likely. (passed 5d ago)
• 4 November 2026, third-quarter 2026 results. uniQure announced the date on 28 October 2026. It is the first scheduled chance to describe FDA correspondence, confirmatory-study design and launch-related spending. (passed 2d ago)

What would change the view

The case breaks if the FDA refuses to file the BLA, grants only standard review in a way that pushes a decision well past 2027, or tells the company that a randomized sham-surgery-controlled trial is required. Later follow-up showing continued decline in high-dose patients, or a new treatment-related serious adverse event, would weaken it further. A cash runway statement shorter than the 2030 funding horizon, or a new equity offering, would also count against it.

On price, a daily close below $20, under the 15 October 2026 close of $22.52, would end the thesis. An acceptance with priority review and a clear review timeline, confirmed in the 4 November 2026 report, would remove the main regulatory doubt and strengthen the case.

What it trades with

QURE trades on its own regulatory path, with a single asset and revenue of $5.8M in the second quarter of 2026. Gene-therapy peers react to FDA tone on external controls and accelerated approval; Benzinga reported on 22 June 2026 that the FDA reversed its rejection of Regenxbio's Navsunli, allowing a refiling. Moves in the broader biotech index matter less than the agency's treatment of small, externally controlled datasets.